DuraLock-C Catheter Lock Solution

Exclusion criteria

• ✕. Able to give informed consent after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period.
• ✕. Patients undergoing HD 3 or 4 times per week in clinic (expected to continue for the length of the study) with an established or newly placed non-tunneled or tunneled HD CVC as primary vascular access.
• ✕. Adult male or female patients, aged ≥18 years at the time of screening.
• ✕. Clinically stable as judged by the treating physician and as demonstrated by stable medical history for 30 days prior to enrollment, physical examination, and laboratory testing.
• ✕. Expected to survive for the next 6 months and the patient is likely to require the use of a CVC for at least 90 days.
• ✕. Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at screening